Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 10/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.41 |
| ▸ | MICA | Q29983 | 1/20 | 0.41 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027986 | 0.94 | MTTP (0.64) | MTTPKLRK1MICARAET1L | |
| SCHEMBL14028000 | 0.92 | MTTP (0.52) | MTTPMAPTTP53RXFP1THRB | |
| SCHEMBL14027789 | 0.89 | MTTP (0.59) | MTTPMAPTTP53KLRK1MICA | |
| SCHEMBL14027939 | 0.89 | MTTP (0.59) | MTTPMAPTTP53KLRK1MICA | |
| SCHEMBL14027988 | 0.84 | MTTP (0.57) | MTTP | |
| SCHEMBL14028004 | 0.83 | MTTP (0.46) | MTTPMAPTTP53KLRK1MICA | |
| SCHEMBL14027895 | 0.81 | MTTP (0.51) | MTTPMAPTTP53KLRK1MICA | |
| SCHEMBL4941037 | 0.81 | MTTP (0.56) | MTTPMAPTTP53KLRK1MICA | |
| SCHEMBL4941034 | 0.81 | MTTP (0.56) | MTTPMAPTTP53KLRK1MICA | |
| SCHEMBL14027887 | 0.80 | MTTP (0.50) | MTTPMAPTTP53KLRK1MICA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | MTTP 1/4885MAPT 2403/4885TP53 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.